Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
New England Journal of Medicine2015Vol. 373(14), pp. 1318–1328
Citations Over TimeTop 1% of 2015 papers
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Abstract
Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).
Related Papers
- → Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3(2022)11 cited
- → Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials(2017)22 cited
- → An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis(2020)10 cited
- → Ixekizumab treatment results in more rapid clinical improvements in patients with moderate-to-severe psoriasis compared with ustekinumab: Results from the IXORA-S trial(2019)1 cited
- → Ixekizumab efficacy and safety in moderate-to-severe genital psoriasis(2018)